Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossif...
Last blueprint medicines corp earnings: 8/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
| Impact snapshot | Event time: | BPMC | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
BPMC alerts
BPMC alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corp news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Shareholders Are Thrilled That The Blueprint Medicines (NASDAQ:BPMC) Share Price Increased 153% [Yahoo! Finance News]Yahoo! Finance News
- Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)Business Wire
- Blueprint Medicines Corp (NASDAQ: BPMC) had its price target lowered by analysts at Morgan Stanley from $110.00 to $109.00. They now have an "overweight" rating on the stock.MarketBeat
- Blueprint Medicines Corp (NASDAQ: BPMC) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Blueprint Medicines Corp (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Cowen Inc.MarketBeat
- More
BPMC
SEC Filings
- 10/16/19 - Form 8-K
- 9/27/19 - Form CT
- 9/18/19 - Form 4
- BPMC's page on the SEC website
- More